Small Lymphocytic Leukemia (SLL) (DBCOND0117330)

Identifiers

Synonyms

Leukemia, Small Lymphocytic / Small Lymphocytic Leukemia

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT03824483	Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)	Obinutuzumab Venetoclax Zanubrutinib	treatment	2	recruiting
NCT04209621	Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Duvelisib Ibrutinib	treatment	2	terminated
NCT04198415	A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)	No drug interventions	Not Available	Not Available	completed
NCT00546793	Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL	Veltuzumab	treatment	1 / 2	completed
NCT04189952	Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma	Acalabrutinib Carboplatin Etoposide Ifosfamide Rituximab	treatment	2	terminated
NCT01066663	Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Pyrimethamine	treatment	1 / 2	completed
NCT04018248	BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I)	BR101801	treatment	1	active_not_recruiting
NCT05621148	REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy	No drug interventions	Not Available	Not Available	completed
NCT02361346	Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL	No drug interventions	treatment	1 / 2	terminated
NCT03207555	Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)	Ibrutinib	treatment	2	completed
NCT00109356	Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia	No drug interventions	treatment	1 / 2	unknown_status
NCT02556346	Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma	No drug interventions	treatment	1	withdrawn
NCT00543114	Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL	Fludarabine Lenalidomide Rituximab	treatment	1	terminated
NCT03329950	A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies	CDX-301 Pembrolizumab	treatment	1	completed